UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

TWI PHARMACEUTICALS, INC., Petitioner,

v.

MERCK SERONO SA, Patent Owner.

Case IPR2023-00049 U.S. Patent No. 7,713,947

DECLARATION OF GILLIAN T. FARRELL
IN SUPPORT OF MOTION FOR ADMISSION *PRO HAC VICE*

Merck 2073 TWi v Merck



I, Gillian T. Farrell, declare as follows:

- 1. I was admitted to the Massachusetts Bar in 2019 and the New York Bar in 2020. I have been practicing law for four years, with an emphasis on patent litigation in a variety of jurisdictions. I have had significant involvement in patent disputes in district court litigation. As part of my patent litigation experience, I have knowledge and experience with litigating invalidity/validity, defending and deposing fact and expert witnesses, handling evidentiary issues, and claim construction.
- 2. I am a member in good standing of the Bars of Massachusetts and New York and am admitted to practice before the U.S. District Court for the District of Massachusetts.
- 3. My Massachusetts Bar membership number is 705331. My New York Bar membership number is 5752670.
- 4. I have never been suspended or disbarred from practice before any court or administrative body.
- 5. I have never had a court or administrative body deny my application for admission to practice.
- 6. I have never had any sanctions or contempt citations imposed on me by any court or administrative body.



- 7. I have read and will comply with the Patent Office Trial Practice
 Guide and the Board's Rules for Practice for Trials, as set forth in 37 C.F.R. Part
 42.
- 8. I agree to be subject to the United States Patent and Trademark
 Office Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
- 9. I have not appeared *pro hac vice* before the United States Patent and Trademark Office in the last three years.
- 10. I am intimately familiar with the subject matter at issue in this proceeding. I participated in reviewing the papers filed in this proceeding. In addition to this proceeding, I participated in reviewing papers in the related *inter partes* review matters challenging U.S. Patent No. 7,713,947 (the "'947 patent") and U.S. Patent No. 8,377,903 (the "'903 patent"), which were filed as *Hopewell Pharma Ventures, Inc., v. Merck Serono SA*, IPR2023-00480, and *Hopewell Pharma Ventures, Inc., v. Merck Serono SA*, IPR2023-00481, respectively. Moreover, I am currently representing Merck KGaA, Merck Serono SA, and Ares Trading SA (collectively, "Merck") in the following consolidated district court litigation, in which the '947 patent is a patent-in-suit: *Merck KGaA, Merck Serono SA*, and *Ares Trading SA v. Hopewell Pharma Ventures, Inc., et al.*, No. 1:22-cv-



01365-GBW (consolidated)¹ (D. Del.).

- 11. I will work in coordination and association with the designated lead counsel, Emily R. Whelan, for the duration of my involvement in this proceeding.
- 12. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine, imprisonment, or both under Section 1001 of Title 18 of the United States Code.

¹ The following cases have been consolidated as *Merck KGaA*, *Merck Serono SA*, and *Ares Trading SA v. Hopewell Pharma Ventures, Inc., et al.*, No. 1:22-cv-01365-GBW (D. Del.): *Merck KGaA*, *Merck Serono SA*, and *Ares Trading SA v. Hopewell Pharma Ventures, Inc.*, No. 1:22-cv-01365-GBW (D. Del.); *Merck KGaA*, *Merck Serono SA*, and *Ares Trading SA v. Aurobindo Pharma USA*, *Inc.* and *Aurobindo Pharma Limited*, No. 1:23-cv-00039-GBW (D. Del.); and *Merck KGaA*, *Merck Serono SA*, and *Ares Trading SA v. Apotex Inc.* and *Apotex Corp.*, No. 1:23-cv-00655-GBW (D. Del.).



Dated: March 25, 2024

Respectfully Submitted,

/Gillian T. Farrell/

Gillian T. Farrell Wilmer Cutler Pickering Hale and Dorr LLP 7 World Trade Center 250 Greenwich Street New York, NY 10007 (212) 230-8800

